# CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Source: https://onco.cc/trials/nct06179524/  
OnCo record `nct06179524` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of CAR-T-19 cell injection in acute lymphoblastic leukaemia, run by Beijing Yongtai Ruike Biotechnology Company Ltd, now recruiting.

## Summary

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL is a phase 2 interventional study registered as NCT06179524 by Beijing Yongtai Ruike Biotechnology Company Ltd, with 100 participants planned, started 2024-01-03 and due to reach its primary completion in 2025-06-30. Interventions recorded: CAR-T-19 cell injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06179524
- Phase: 2
- Setting: Phase II Clinical Study of CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/refractory B-cell Acute Lymphoblastic Leukemia(B-ALL) Under 25 Years of Age (inclusive)
- Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06179524: https://clinicaltrials.gov/study/NCT06179524

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)

---
JSON: https://onco.cc/api/v1/entities/nct06179524.json